Viridian inks Japan licensing deal as it seeks to rival Amgen’s Tepezzanews2025-07-30T08:00:56+00:00July 30th, 2025|Endpoints News|
FDA approves PTC’s rare genetic disease drugnews2025-07-29T12:58:43+00:00July 29th, 2025|Endpoints News|
Exelixis axes late-stage plans for TKI drug in head and neck cancer as Q2 earnings disappointnews2025-07-29T12:28:27+00:00July 29th, 2025|Endpoints News|
Novo Nordisk downgrades sales expectations by 5% to 7%news2025-07-29T11:32:34+00:00July 29th, 2025|Endpoints News|
AstraZeneca reports revenue growth, pipeline tweaks as it ponders price cuts, direct-to-patient salesnews2025-07-29T11:07:58+00:00July 29th, 2025|Endpoints News|
Updated: Merck announces $3B in cost cutsnews2025-07-29T10:30:36+00:00July 29th, 2025|Endpoints News|
Apellis and Sobi’s Empaveli clinches FDA approval for rare kidney diseasesnews2025-07-29T08:25:34+00:00July 29th, 2025|Endpoints News|
Bristol Myers sends five immunology assets to new $300M biotechnews2025-07-29T02:16:36+00:00July 29th, 2025|Endpoints News|
Kennedy pledges to ‘fix’ the vaccine injury compensation programnews2025-07-28T18:59:57+00:00July 28th, 2025|Endpoints News|
